Drug firm Lupin on Thursday said that in alliance with Concord Biotech, it has received approval from the US health regulator to market generic immunosuppressant Tacrolimus capsules used in the American market.
In alliance with Concord Biotech, the company has received approval from the United States Food and Drug Administration (USFDA) to market Tacrolimus capsules USP, in the strengths of 0.5 mg, 1 mg, and 5 mg, Lupin said in a filing to the BSE.
The product is a generic version of Astellas Pharma US, Inc’s Prograf capsules in the same strengths, it added.
According to IQVIA MAT September 2020 data, Tacrolimus capsules USP (0.5 mg, 1 mg, and 5 mg) had an annual sales of about $303 million in the US, Lupin said.
The capsules are indicated for the prophylaxis of organ rejection in adult and pediatric patients receiving allogeneic liver, kidney or heart transplants, in combination with other immunosuppressants, it added.
Shares of Lupin Ltd on Thursday fell 1.76 per cent to Rs 897.70 per scrip on the BSE.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.